Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FDPS | P14324 | 20/20 | 0.56 |
| ▸ | GGPS1 | O95749 | 8/20 | 0.56 |
| ▸ | PDE3A | Q14432 | 3/20 | 0.56 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.56 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.48 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Olpadronic Acid SCHEMBL138988 | 0.98 | FDPS (0.58) | FDPSGGPS1PDE3AAGTR1OPRM1 | |
| Olpadronic Acid SCHEMBL9581942 | 0.88 | FDPS (0.69) | FDPSGGPS1PDE3AAGTR1OPRM1 | |
| SCHEMBL12631211 | 0.87 | FDPS (0.49) | FDPSGGPS1PDE3AAGTR1OPRM1 | |
| Olpadronic Acid SCHEMBL7457593 | 0.85 | FDPS (0.71) | FDPSGGPS1PDE3AAGTR1OPRM1 | |
| SCHEMBL3976360 | 0.84 | FDPS (0.57) | FDPSGGPS1PDE3AAGTR1OPRM1 | |
| Olpadronic Acid SCHEMBL5717996 | 0.84 | FDPS (0.55) | FDPSGGPS1PDE3AAGTR1OPRM1 | |
| SCHEMBL9333595 | 0.83 | FDPS (0.61) | FDPSGGPS1PDE3AAGTR1OPRM1 | |
| SCHEMBL8050318 | 0.82 | FDPS (0.45) | FDPSGGPS1PDE3AAGTR1OPRM1 | |
| SCHEMBL16091938 | 0.81 | FDPS (0.62) | FDPSGGPS1PDE3AAGTR1OPRM1 | |
| SCHEMBL9333367 | 0.81 | FDPS (0.62) | FDPSGGPS1PDE3AAGTR1OPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 66 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230381323-A1 | RELEASABLE CONJUGATES | FISH & RICHARDSON PC | 2023-11-30 | — | — | US | disclosed |
| US-11786599-B2 | Releasable conjugates | QUIAPEG PHARMACEUTICALS AB (SE) | 2023-10-17 | — | — | US | disclosed |
| EP-4011396-A1 | RELEASABLE CONJUGATES | QuiaPEG Pharmaceuticals AB (SE) | 2022-06-15 | — | — | EP | disclosed |
| EP-3592393-B1 | RELEASABLE CONJUGATES | QUIAPEG PHARMACEUTICALS AB (SE) | 2021-12-01 | — | — | EP | disclosed |
| US-20180360974-A1 | RELEASABLE CONJUGATES | FISH & RICHARDSON PC | 2018-12-20 | — | — | US | disclosed |
| EP-2566847-B1 | NOVEL IMMUNOMODULATOR AND ANTI INFLAMMATORY COMPOUNDS | ICOZEN THERAPEUTICS PVT LTD (IN) | 2018-11-07 | — | — | EP | disclosed |
| WO-2018163131-A1 | RELEASABLE CONJUGATES | QUIAPEG PHARMACEUTICALS AB (SE) | 2018-09-13 | — | — | WO | disclosed |
| CN-106006593-B | A kind of nano-calcium phosphate preparation method of simple and effective | 西南交通大学 | 2018-08-17 | — | — | CN | disclosed |
| US-9758474-B2 | Immunomodulator and anti-inflammatory compounds | INCOZEN THERAPEUTICS PVT. LTD. (IN) | 2017-09-12 | — | — | US | disclosed |
| CN-104628768-A | Preparation method of sodium ibandronate | JIANGSU CHIATAI QINGJIANG PHARMACEUTICAL CO LTD | 2015-05-20 | — | — | CN | disclosed |
| WO-2009021696-A1 | AZABIPHENYLAMINOBENZOIC ACID DERIVATIVES AS DHODH INHIBITORS | ALMIRALL, S.A. (ES) | 2009-02-19 | — | — | WO | disclosed |
| CN-101250201-A | Technetium-99m marked triazole diphosphonic acid complex and preparation method thereof | JIANGSU INST OF NUCLEAR MED (CN) | 2008-08-27 | — | — | CN | disclosed |
| WO-2008077639-A1 | AMINO NICOTINIC AND ISONICOTINIC ACID DERIVATIVES AS DHODH INHIBITORS | LABORATORIOS ALMIRALL, S.A. (ES) | 2008-07-03 | — | — | WO | disclosed |
| CN-100393700-C | Cathepsin cysteine protease inhibitors | MERCK FROSST CANADA INC (CA) | 2008-06-11 | — | — | CN | disclosed |
| CN-101045736-A | Double phospho acid compound of 99mT.C. mark and preparation method | JIANGSU ATOMIC MEDICINE INST (CN) | 2007-10-03 | — | — | CN | disclosed |
| CN-1812967-A | Cathepsin cysteine protease inhibitors | MERCK FROSST CANADA INC (CA) | 2006-08-02 | — | — | CN | disclosed |
| EP-0800397-B1 | BONE MASS ANABOLIC COMPOSITION COMPRISING OLPADRONATE | GADOR SA (AR) | 2006-04-05 | — | — | EP | disclosed |
| US-5885973-A | Bone mass anabolic composition comprising olpadronate | GADOR, S.A. (AR) | 1999-03-23 | — | — | US | disclosed |
| EP-0800397-A1 | BONE MASS ANABOLIC COMPOSITION COMPRISING OLPADRONATE | GADOR S.A. (AR) | 1997-10-15 | — | — | EP | disclosed |
| WO-1996019998-A1 | BONE MASS ANABOLIC COMPOSITION COMPRISING OLPADRONATE | GADOR S.A. (AR) | 1996-07-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180360974-A1 | RELEASABLE CONJUGATES | GUSB, ABCB11, UGT2B7 | FDPS 1839/4885GGPS1 2170/4885PDE3A 831/4885 |
| US-20230381323-A1 | RELEASABLE CONJUGATES | GUSB, ABCB11, UGT2B7 | FDPS 1839/4885GGPS1 2170/4885PDE3A 831/4885 |
| US-11786599-B2 | Releasable conjugates | GUSB, ABCB11, UGT2B7 | FDPS 1839/4885GGPS1 2170/4885PDE3A 831/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.